Abstract: This study describes the consensus opinion of the participants of the third Yale Workshop on probiotic use. There were 10 experts participating. The recommendations update those of the first 2 meetings that were published in 2005 and 2008. The workshop presentations and papers in this supplement relate to the involvement of normal microbiota involved in intestinal microecology, how the microbes interact with the intestine to affect our immunologic responses, the stability and natural history of probiotic organisms, and the role of the intestinal microbatome with regard to affecting cardiac risk factors and obesity. Recommendations for the use of probiotics in necrotizing enterocolitis, childhood diarrhea, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile diarrhea are reviewed. As in previous publications, the recommendations are given as A, B, or C ratings. The recent positive experiences with bacteriotherapy (fecal microbiome transplant) are also discussed in detail and a positive recommendation is made for use in severe resistant C. difficile diarrhea.
T he first Yale Workshop on Probiotics was convened in 2004. The clinical use of probiotics had gained worldwide attention of patients and health care delivery personnel, but although there was a growing literature on clinical trials, there were few clinical recommendations. Hence, we gathered thought leaders and investigators in the field and published the first workshop recommendations in 2005. 1 We held the second workshop with some of the original contributors but added others to broaden our view. The results of the second workshop were published in 2008. 2 This paper 3 represents the work of 10 experts of the third Yale Workshop held in New Haven in April 2011.
Dr Walker and I designed this program in an effort to include the newer concepts on the use of probiotics to maintain health. The work presented explores probiotic interaction with the immune system. 4 The importance of these interactions to overall host health is not yet fully understood. Questions such as how much do supplemental probiotic organisms contribute to immune status compared with the natural physiologic effects of the microbiome?, can a single organism have an important impact?, or are multiple organisms needed? are discussed. 5 We also included in this workshop a discussion of the effects of colonic fermentation on health 6 and how it may affect cardiac risk factors. The early concepts of how the microbiome may affect obesity also are covered. 7 The supplement includes detailed articles on all of these factors.
We reviewed the recommendations in diseases made in 2005 and 2008 and updated them. Updates on inflammatory bowel disease, 8 the irritable bowel syndrome, 9 infectious diarrhea, 10 and Clostridium difficile infection are given.
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The user should be aware that some of the recommendations were made by the investigators of the first 2 workshops. All authors have cleared this publication, but there is still controversy on some of the diseases of the designations of an A, B, or C rating.
We have continued to use the rating system first used in our 2005 report. This is an arbitrary system. As noted in encyclopedic references, 12 there are many rating systems, and in clinical evidence-based medicine, they are frequently controversial. We used "A" recommendation to mean strong, positive studies in the literature. "B" recommendation is based on positive-controlled studies, but the presence of some negative studies that did not support the primary outcome. "C" recommendation is based on some positive studies, but 2 The first recommendation was made for necrotizing enterocolitis particularly because of the published papers on the subject from Taiwan in 2008 which were very encouraging and the strong meta-analysis literature. However, it must be stressed that if probiotics are used, the strains used in a specific reference should be followed. 13, 47 Finally, as there is now clinical evidence that transplanting the entire intestinal microbiota is beneficial in severe relapsing C. difficile diarrhea, we have presented that information as part of our recommendations. 14 We would like to emphasize that these recommendations are based on the literature that is available at this time. It must also be stressed that these recommendations are strain specific. Strains are listed in the table for most, but when not listed, we provide references that can be consulted for the strain. Anyone using these recommendations must refer to the reference and the specific strain used in referenced studies. 15 LGG, 16 Lactobacillus reuteri SD2112 17 15-18 Prevention of infection B S. boulardii, 15 LGG 16 15,16,18 Prevention of AAD A S. boulardii. 19 LGG, 20 combination of Lactobacillus casei DN114 G01, Lactobacillus bulgaricus, snf Saccharomyces thermophilus 21 19-21 Prevention of recurrent CDAD B/C S. boulardii, 11 LGG, 22 bacteriotherapy 14 11,12,14,22 Prevention of CDAD B/C LGG, 11 S. boulardii 22 11,22 IBD Pouchitis Preventing and maintaining remission A VSL#3 23-25 23-25 Induce remission C VSL#3 26 26 Ulcerative Lactobacillus plantarum 299V 39 39 Necrotizing Enterocolitis B Lactobacillus acidophilus NCDO1748 13 and Bifidobacterium bifidium NCDO1453 Allergy Atopic eczema associated with cow's milk allergy Treatment A LGG, Bifidobacterium lactis 41 41 Prevention A LGG, B. lactis 41 41 Radiation enteritis C VSL#3, 42 L. acidophilus 43 42,43 Vaginosis and vaginitis C L. acidophilus, 44 Lactobacillus rhamnosus GR-1, 45 L. reuteri RC14 46 44-46 *Check 2008 references for further elaboration on strains used and their availability. wReference 48 was made available after the workshop meeting on April 8, 2011 but believed to be significant enough to qualify this probiotic to be in a B category.
AAD indicates antibiotic-associated diarrhea; CDAD, Clostridium difficile-associated diarrhea; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; LGG, Lactobacillus GG.
There are now many published meta-analyses and ratings published and those are referred to in the articles in this supplement. We hope that this review will be helpful to clinicians seeking clinical advice on the use of probiotics.
